AroCell AB announces today that a research poster submitted by Kiran Kumar J et al entitled “The AroCell TK 210 ELISA may complement Pro PSA and the Prostate Health Index in differentiating pre-cancerous and cancerous conditions in prostate cancer” was accepted by the AARC for presentation at their annual meeting in April 2017. The purpose of this study was to compare the AroCell TK 210 ELISA with PSA, free PSA, pro PSA and PHI in men with pre-cancerous conditions and patients with confirmed prostate cancer.